CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury.
CVS-1123, low-molecular-weight, direct thrombin inhibitor was studied in an anesthetized canine model of arterial and venous thrombosis to determine whether thrombin inhibition could reduce the incidence of occlusive thrombosis in response to vessel-wall injury. The left carotid artery (LCA) and right jugular vein (RJV) were instrumented with a flow probe, intraluminal electrode, and critical stenosis. Either saline (n = 9), or CVS-1123 (n = 12) was administered in a loading dose of 2 mg/kg i.v., followed by an infusion (2.46 mg/kg/h for 180 min). Vessel-wall injury was initiated by applying a 300-microA anodal current to the intimal surface of the LCA and RJV. Platelet aggregation in response to gamma-thrombin remained inhibited by CVS-1123 for 8 h. The activated partial thromboplastin time (aPTT) was increased and remained elevated for the duration of the protocol. The prothrombin time (PT) showed an initial increase and then a rapid decrease after the infusion was discontinued. There was a twofold increase in the bleeding time (BT) at 2 h. The time to occlusion of the LCA was prolonged (380 +/- 22 min in the CVS-1123 group vs. 152 +/- 18 min in the saline group) with seven of 12 patent arteries at 8 h. Similarly, the time to occlusion for RJV was prolonged (415 +/- 16 min in the CVS-1123 group vs. 99 +/- 8 min in the saline group) with eight of 12 veins remaining patent at 8 h. CVS-1123 administration was associated with a decrease in the thrombus weights in both the LCA and RJV as compared with the saline-treated animals. In summary, CVS-1123 modifies the thrombogenic response to deep vessel-wall injury in both the arterial and venous circulations. The results suggest that CVS-1123 is an effective antithrombin and may offer a therapeutic alternative to current antithrombins in the management of arterial and venous thrombosis.
Rebello
S S
SS
Department of Pharmacology, University of Michigan Medical School, Ann Arbor 48109-0632, USA.
Miller
B V
BV
Basler
G C
GC
Lucchesi
B R
BR
D000818:Animals; D000990:Antithrombin III / Q000032:analysis; D000991:Antithrombins / Q000494:pharmacology*; D001157:Arterial Occlusive Diseases / Q000517:prevention & control; D001777:Blood Coagulation / Q000187:drug effects; D004285:Dogs; D005260:Female; D008297:Male; D009842:Oligopeptides / Q000097:blood / Q000494:pharmacology*; D010447:Peptide Hydrolases / Q000032:analysis; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D013924:Thrombophlebitis / Q000517:prevention & control*; D013927:Thrombosis / Q000517:prevention & control*
D000991:Antithrombins; C101948:CVS 1123; D009842:Oligopeptides; D010975:Platelet Aggregation Inhibitors; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D010447:Peptide Hydrolases